Consultants Forum Advertise
Subscribe
Close

  • Free for qualified executives and consultants to industry

  • Receive quarterly issues of Area Development Magazine and special market report and directory issues

Subscribe Now
Renew

Area Development - Site Selection, Facility Planning and Workforce Development

Frontline: Red Sea Pharma Crisis Pushing Logistics Advancements

Companies need to navigate the stormy waters of the Red Sea amid Houthi threats and global supply chain challenges.

Q2 2024
The United Arab Emirates (UAE) has established itself as a critical hub in the global pharmaceutical supply chain, attracting major players like Sanofi, Novartis, and Pfizer. This prominence is due to its strategic location, advanced logistics infrastructure, and conducive business environment. However, the stability of this hub is under threat due to increasing regional tensions, particularly the Houthi militia's missile attacks on commercial vessels in the Red Sea, a vital conduit for global trade.

Lisa Anderson, president of LMA Consulting Group, captures the essence of the situation: “The rebels are not predictable in their attacks on ships in the Red Sea area.” These disruptions have led to significant logistical challenges, including the need for rerouting shipping lanes which, according to Anderson, “adds two weeks to the trip” when vessels are diverted around the Cape of Good Hope.

The impact on the pharmaceutical industry is notable, with increased transit times and freight rates affecting the cost structure and supply chain efficiency. The diversion of shipping routes to avoid the conflict zones has led to more than a 100 percent increase in shipping costs. This change disproportionately affects the delivery of pharmaceutical products, where timeliness and cost-efficiency are paramount.

Jeremy Tancredi, partner and supply chain leader at West Monroe, notes the specific impact on the pharmaceutical sector: “Most of the pharma products that travel through the Red Sea are generic drugs made in India.” The disruption, therefore, significantly affects the global supply of generics, which are crucial for many healthcare systems.

They had been reluctant to move to regional manufacturing because it represents a significant investment. But you have to make sure you are ahead of these types of problems. Lisa Anderson, president, LMA Consulting Group “The strategic situation is complex at the minute, because there are so many problems in the Panama and Suez Canals, and there are only so many shipping routes,” Anderson says.”

Faced with these challenges, pharmaceutical may be reassessing their supply chain strategies. The industry, historically reliant on efficient, just-in-time manufacturing and delivery models, is likely contemplating more robust approaches to mitigate risks. Anderson mentions that some firms are considering regional manufacturing to reduce dependency on vulnerable shipping routes.

Anderson said some pharma firms are accelerating their shift to regional manufacturing, to reduce their exposure to shipping problems. “They had been reluctant to move to regional manufacturing because it represents a significant investment,” she explains. “But you have to make sure you are ahead of these types of problems. No one expected to have so many problems at one time.”

It's worth noting that several major pharmaceutical companies declined to comment on this story, with one saying that they were “monitoring the situation.”

Logistical Alternatives
In adapting to these disruptions, companies like Dr. Reddy’s Laboratories are exploring various logistical alternatives. Erez Israeli, CEO of Dr. Reddy’s, highlighted in a conference call the firm's strategy to leverage air freight and increase inventory levels in less volatile regions, such as the United States. These measures aim to create a buffer against supply chain disruptions and ensure continuity in pharmaceutical delivery.

The broader industry trend indicates a shift toward strategic diversification in manufacturing and logistics. This includes exploring nearshoring or reshoring options to bring production closer to end markets, thereby reducing the transit risks and complexities associated with long-distance maritime shipping.

Moreover, the escalating shipping costs and the operational risks of maritime transport have prompted pharmaceutical companies to innovate in logistics management. Advanced technologies — such as real-time tracking, blockchain for secure and transparent supply chain operations, and IoT devices for monitoring shipment conditions — are becoming increasingly prevalent. These technologies enable companies to maintain visibility and control over their supply chains, enhancing their ability to respond proactively to disruptions.

The escalating shipping costs and the operational risks of maritime transport have prompted pharmaceutical companies to innovate in logistics management. Larger pharmaceutical companies, with more resources at their disposal, are leading the way in adopting these advanced supply chain strategies. For instance, Pfizer’s development of shipping containers that double as ultra-cold freezers exemplifies how companies are innovating to maintain the integrity of drug shipments under challenging conditions.

Trucking is another option, albeit less desirable due to higher costs and lower carrying capacity. According to the Business Standard, an Israeli software company called Trucknet Enterprise Ltd. Is sending chemicals, food, plastics, and electronics from ports in the United Arab Emirates and Bahrain, through Saudi Arabia and Jordan, on to Israel and on to Europe.

Shipping giant Maersk has begun offering truck bridge services in the region, essentially a land-based relay of cargo in the Gulf. These services are designed to bypass maritime chokepoints, offering a faster, more reliable alternative to traditional sea routes affected by the crisis. By integrating trucking solutions with their sea transport operations, Maersk is able to mitigate the impact of increased transit times and higher operational costs that have arisen from the need to navigate longer routes around the Cape of Good Hope.

These technological advancements not only safeguard product quality but also extend the reach of life-saving medicines to remote and underserved regions.

The reliance on digital technologies has also grown, with companies integrating sophisticated data analytics and predictive modeling to anticipate supply chain disruptions and optimize logistics planning. Building an Agile, Responsive Supply Chain
The reliance on digital technologies has also grown, with companies integrating sophisticated data analytics and predictive modeling to anticipate supply chain disruptions and optimize logistics planning. These capabilities allow for a more agile and responsive supply chain framework, essential in navigating the complexities of the current global trade environment.

The shift in the pharmaceutical industry’s supply chain strategy reflects a broader recognition of the need for resilience in the face of geopolitical and environmental uncertainties. The ongoing situation in the Red Sea underscores the importance of strategic flexibility and the adoption of comprehensive risk management practices.

The pharmaceutical shipping crisis in the Red Sea presents a big challenge for the industry, and it requires a strategic overhaul in supply chain management. For executives, the priority is to navigate these disruptions through a combination of advanced technological integration, strategic geographic diversification, and enhanced operational flexibility. The current crisis serves as a catalyst for reevaluating and strengthening supply chain resilience, ensuring that pharmaceutical companies can maintain uninterrupted access to global markets and safeguard the delivery of essential medicines.

Exclusive Research